Abstract: Tibolone is a drug with complex tissue-specific action that exhibits a combination of estrogenic, progestogenic, and slight androgenic activity. Its variable profile explains its clinical effects, depending on the target tissue where it is metabolized, its metabolites’ affinity for and potency in hormone receptors, and probable enzymatic activity modulation.
In recent reviews and clinical trials, the effectiveness of tibolone in alleviating different hot flush menopause symptoms, mainly in mood and sexuality disorders, has been noted. In Spain, tibolone is the most prescribed hormonal treatment, and one of the most common complaints among postmenopausal women is change in sexual drive. For such reason, a panel of experts from the Spanish Menopause Society met to develop usage recommendations based on the best evidence available.
From the 1Department of Obstetrics and Gynecology, University of Granada, Granada, Spain; 2Hospital Torrecardenas, Almería, Spain; 3Hospital Vall d’Hebron, University of Barcelona, Barcelona, Spain; 4Hospital de Guadalajara, University of Alcalá, Guadalajara, Spain; 5Asturias Central University Hospital, University of Oviedo, Oviedo, Spain; 6Instituto Dexeus, Barcelona, Spain; 7Hospital San Juan, Alicante, Universidad Miguel Hernández, Alicante, Spain; and 8Clínica Diatros, Barcelona, Spain.
Received September 26, 2012; revised and accepted October 25, 2012.
Funding/support: None reported.
Financial disclosure/conflicts of interest: None reported.
Address correspondence to: Nicolas Mendoza, MD, PhD, Maestro Montero, 21, 18004 Granada, Spain. E-mail: firstname.lastname@example.org